Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 387 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Kenalog Clear all
Terminated Phase 3 Interventional Results available

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

NCT05658874
View directory record Official record
Conditions
Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions
Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin
Drug · Procedure · Behavioral + 1 more
Lead sponsor
Jocelyn Fitzgerald
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076
View directory record Official record
Conditions
Bilateral Knee Osteoarthritis
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Torrance, California • Rochester, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing Two Bladder Instillations for IC/BPS

NCT03463915
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Bladder instillation WITH triamcinolone acetonide, Bladder instillation WITHOUT triamcinolone acetonide
Drug
Lead sponsor
Olivia Cardenas-Trowers, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 3, 2026, 10:40 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Biomarker Feedback Intervention

NCT07307326
View directory record Official record
Conditions
High Risk Drinking, College Student Drinking
Interventions
eCHECKUP TO GO (eCTG), eCHECKUPTOGO + brief personalized alcohol biomarker feedback intervention (eCTG + TAC)
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 23 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 4 Interventional

Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

NCT05058209
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Drug
Lead sponsor
ROC Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 3, 2026, 10:40 AM EDT
Terminated Phase 4 Interventional

Local Methotrexate Injections for the Treatment of Nail Psoriasis

NCT06578728
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Methotrexate, Triamcinolone Acetonide 10mg/mL, Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 2 Interventional

Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

NCT00203372
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab 7.5 and TAC, Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), Bevacizumab 15 and TAC, Placebo 15 and TAC
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Los Angeles, California • Pomona, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 3, 2026, 10:40 AM EDT
Withdrawn Not applicable Interventional

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

NCT02457026
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Aflibercept, Triamcinolone Acetonide, Verteporfin
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 3, 2026, 10:40 AM EDT
Not listed Phase 4 Interventional

Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue

NCT02398539
View directory record Official record
Conditions
Hypergranulation Tissue; Gastrostomy Tube Site
Interventions
Silver Nitrate, Triamcinolone
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

NCT00623766
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone, Corticosteroid: Fludrocortisone, Corticosteroid: Hydrocortisone, Corticosteroid: Meprednisone, Corticosteroid: Methylprednisolone, Corticosteroid: Prednisolone, Corticosteroid: Prednisone, Corticosteroid: Triamcinolone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
14
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Not applicable Interventional

Platelet Rich Plasma Versus Corticosteroids in Knee Osteoarthritis Pain

NCT06703970
View directory record Official record
Conditions
Knee Osteoarthritis (OA)
Interventions
Corticosteroid Injection, Platelet Rich Plasma Joint Injection
Drug · Device
Lead sponsor
LifeBridge Health
Other
Eligibility
21 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 3, 2026, 10:40 AM EDT
Terminated Not applicable Interventional Results available

Hydrogel Patch for the Treatment of Eczema

NCT00924508
View directory record Official record
Conditions
Eczema
Interventions
hydrogel patch, Triamcinolone (TAC) 0.1% cream
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 3, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT06790784
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
Procedure · Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
32
States / cities
Huntington Beach, California • Loma Linda, California • Santa Barbara, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide

NCT00791934
View directory record Official record
Conditions
Sinusitis
Interventions
Stratus Microflow Ethmoid Spacer
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 3, 2026, 10:40 AM EDT
Recruiting Not applicable Interventional

Corticosteroid Injection Versus Nerve Block

NCT06735027
View directory record Official record
Conditions
Glenohumeral Arthritis, Rotator Cuff Arthropathy
Interventions
intraarticular corticosteroid injection (IACI), suprascapular nerve block (SSNB)
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

NCT02891603
View directory record Official record
Conditions
Graft Vs Host Disease, GVHD
Interventions
Pacritinib, Sirolimus, Tacrolimus, Allogenic hematopoietic cell transplant (alloHCT)
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Keloids With Fractional Erbium Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid

NCT04786210
View directory record Official record
Conditions
Keloid Scar
Interventions
Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil, Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide
Combination Product
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac for Treatment of Leukemia

NCT00001941
View directory record Official record
Conditions
HTLV-I Infection, T Cell Leukemia
Interventions
daclizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 3, 2026, 10:40 AM EDT
Completed Phase 1Phase 2 Interventional

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT00050648
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, Cyclosporine, cyclosporine and Daclizumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Sep 3, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

NCT07168148
View directory record Official record
Conditions
Nasal Obstruction, Chronic Rhinitis
Interventions
Oxymetazoline + Triamcinolone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 3, 2026, 10:40 AM EDT
Withdrawn Phase 4 Interventional

Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients

NCT03319784
View directory record Official record
Conditions
Rotator Cuff Tear, Rotator Cuff Injury, Rotator Cuff Tendinitis, Diabetes Mellitus
Interventions
Ketorolac, Triamcinolone Acetonide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 3, 2026, 10:40 AM EDT
Recruiting Not applicable Interventional

Topical Treatment for Atopic Dermatitis

NCT06244212
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
9 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 3, 2026, 10:40 AM EDT